Clinical trial
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With…
NCT00426816 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00426816 |
|---|---|
| Title | To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia |
| Official title | A Multi-centre, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of SB-649868 (10, 30 mg and 60 mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sleep Initiation and Maintenance Disorders |
| Intervention type | Drug |
| Interventions | SB-649868, Placebo |
| Enrollment | 48 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jan 25, 2007 |
| Last update posted | Aug 13, 2012 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: